Available evidence to date indicates that mutations in the PMS2 gene confer a lifetime CRC risk of 15–20% (compared to lifetime risk as high as 80% with the other LS-associated MMR genes) (52). The gene discussed is PMS2; the disease is colorectal carcinoma.